iTeos Therapeutics, Inc. (ITOS)
ITOS Stock Price Chart
Explore iTeos Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ITOS price movements and trends.
ITOS Company Profile
Discover essential business fundamentals and corporate details for iTeos Therapeutics, Inc. (ITOS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Jul 2020
Employees
173.00
CEO
Michel Detheux
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
ITOS Financial Timeline
Browse a chronological timeline of iTeos Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$1.33.
Earnings released on 6 Aug 2025
EPS came in at -$1.51 falling short of the estimated -$1.12 by -34.82%.
Earnings released on 28 Apr 2025
EPS came in at -$0.80 surpassing the estimated -$0.94 by +14.89%.
Earnings released on 5 Mar 2025
EPS came in at -$1.01 surpassing the estimated -$1.14 by +11.40%.
Earnings released on 12 Nov 2024
EPS came in at -$1.05 surpassing the estimated -$1.18 by +11.02%.
Earnings released on 8 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$1.04 by +82.69%, while revenue for the quarter reached $35.00M , beating expectations by +3.40K%.
Earnings released on 10 May 2024
EPS came in at -$1.07 falling short of the estimated -$1.02 by -4.90%.
Earnings released on 6 Mar 2024
EPS came in at -$0.85 surpassing the estimated -$1.03 by +17.48%, while revenue for the quarter reached -$11.30M , missing expectations by -190.65%.
Earnings released on 7 Nov 2023
EPS came in at -$0.90 surpassing the estimated -$1.20 by +25.00%.
Earnings released on 8 Aug 2023
EPS came in at -$0.96 surpassing the estimated -$1.03 by +6.80%.
Earnings released on 10 May 2023
EPS came in at -$0.44 surpassing the estimated -$0.99 by +55.56%, while revenue for the quarter reached $12.60M , missing expectations by -76.63%.
Earnings released on 15 Mar 2023
EPS came in at $0.57 surpassing the estimated $0.33 by +72.73%, while revenue for the quarter reached $53.91M , beating expectations by +30.96%.
Earnings released on 10 Nov 2022
EPS came in at $0.03 falling short of the estimated $0.10 by -70.00%, while revenue for the quarter reached $19.49M , missing expectations by -53.20%.
Earnings released on 10 Aug 2022
EPS came in at $0.15 falling short of the estimated $1.20 by -87.50%, while revenue for the quarter reached $41.72M , missing expectations by -51.24%.
Earnings released on 12 May 2022
EPS came in at $1.82 surpassing the estimated $0.80 by +127.50%, while revenue for the quarter reached $152.52M , beating expectations by +140.95%.
Earnings released on 23 Mar 2022
EPS came in at $4.89 surpassing the estimated $1.28 by +282.03%, while revenue for the quarter reached $240.50M , beating expectations by +181.44%.
Earnings released on 10 Nov 2021
EPS came in at $1.86 falling short of the estimated $4.95 by -62.42%, while revenue for the quarter reached $104.27M , missing expectations by -31.59%.
Earnings released on 12 Aug 2021
EPS came in at -$0.75 falling short of the estimated -$0.41 by -82.93%.
Earnings released on 13 May 2021
EPS came in at -$0.39 surpassing the estimated -$0.48 by +18.75%.
Earnings released on 24 Mar 2021
EPS came in at -$0.43 falling short of the estimated -$0.42 by -2.38%.
Earnings released on 12 Nov 2020
EPS came in at -$0.48 falling short of the estimated -$0.36 by -33.33%.
ITOS Stock Performance
Access detailed ITOS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.